Sugi Predict

Sugi Predict / Compounds / SCHEMBL140991

SCHEMBL140991

SCHEMBL140991

[CH2]CC12CC3CC(CC(C3)C1)C2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIN2D O15399 5/20 0.52
▸ GRIN3B O60391 5/20 0.52
▸ GRIN1 Q05586 5/20 0.52
▸ GRIN2A Q12879 5/20 0.52
▸ GRIN2B Q13224 5/20 0.52
▸ GRIN2C Q14957 5/20 0.52
▸ GRIN3A Q8TCU5 5/20 0.52
▸ ALDH1A1 P00352 3/20 0.39
▸ TSHR P16473 2/20 0.39
▸ LMNA P02545 2/20 0.38
▸ SLC22A2 O15244 1/20 0.38
▸ SLC22A1 O15245 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ STAT6 P42226 1/20 0.38
▸ SLC47A1 Q96FL8 1/20 0.38
▸ SIGMAR1 Q99720 1/20 0.38
▸ CA12 O43570 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL891670 0.78 GRIN2D (0.60) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL2757 0.77 GRIN2D (0.56) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL5251164 0.76 GRIN2D (0.61) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL10957944 0.75 GRIN2D (0.76) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL8413718 0.75 GRIN2D (0.59) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL58465 0.75 GRIN2D (0.59) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7259186 0.73 GRIN2D (0.58) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL11697939 0.73 GRIN2D (0.68) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL27619141 0.73 PKM (0.47) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL919840 0.71 CA12 (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024003259-A1 TEAD INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2024-01-04 — — WO claimed
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2023-11-02 — — US claimed
US-20230174486-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2023-06-08 — — US claimed
CN-115867534-A Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2023-03-28 — — CN claimed
EP-4146623-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF Alectos Therapeutics Inc. (CA) 2023-03-15 — — EP claimed
EP-4146624-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF Alectos Therapeutics Inc. (CA) 2023-03-15 — — EP claimed
CN-115803025-A Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2023-03-14 — — CN claimed
US-11530234-B2 CD73 inhibitors and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2022-12-20 — — US claimed
CN-112759545-B 3- (dimethylamino methyl) piperidine-4-alcohol derivative and preparation method and pharmaceutical application thereof 复旦大学 2022-12-13 — — CN claimed
US-20220213058-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2022-07-07 — — US claimed
WO-1991018888-A1 N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1991-12-12 — — WO claimed
EP-0174956-B1 SOFT $g(b)-ADRENERGIC BLOCKING AGENTS BODOR, Nicholas S. (US) 1990-08-16 — — EP claimed
US-4948813-A Benzylketone phospholipase A2 inhibitors E. I. DU PONT DE NEMOURS AND COMPANY (US) 1990-08-14 — — US claimed
CN-1040193-A The preparation of alkoxyl group-4 (1H)-Pyridione derivatives GOEDECKE AG (DE) 1990-03-07 — — CN claimed
US-4829086-A Soft β-adrenergic blocking agents IVAX International GmbH (CH) 1989-05-09 — — US claimed
US-4782149-A INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVES HOFFMAN-LA ROCHE INC. (US) 1988-11-01 — — US claimed
US-4757069-A Hypotensive agents HOFFMANN-LA ROCHE INC. (US) 1988-07-12 — — US claimed
EP-0174956-A1 SOFT -g(b)-ADRENERGIC BLOCKING AGENTS. BODOR NICHOLAS S 1986-03-26 — — EP claimed
WO-1985004168-A1 SOFT beta-ADRENERGIC BLOCKING AGENTS BODOR NICHOLAS S 1985-09-26 — — WO claimed
EP-0023865-A2 New glycolipid compounds, process for preparation and use as immunological adjuvant MERCK & CO. INC. (US) 1981-02-11 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA GRIN2D 4334/4885GRIN3B 2677/4885GRIN1 3302/4885
US-20220213058-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA GRIN2D 4334/4885GRIN3B 2677/4885GRIN1 3302/4885
US-20230174486-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA GRIN2D 4334/4885GRIN3B 2677/4885GRIN1 3302/4885
US-11530234-B2 CD73 inhibitors and pharmaceutical uses thereof ENTPD5, ENTPD1, NT5E GRIN2D 4128/4885GRIN3B 2853/4885GRIN1 2629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.